Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

Autor: Céline, Louapre, Michella, Ibrahim, Elisabeth, Maillart, Basma, Abdi, Caroline, Papeix, Bruno, Stankoff, Anne-Laure, Dubessy, Caroline, Bensa-Koscher, Alain, Créange, Zina, Chamekh, Catherine, Lubetzki, Anne-Geneviève, Marcelin, Jean-Christophe, Corvol, Valérie, Pourcher, Sylvie, Forlani

Publikováno v: Journal of Neurology, Neurosurgery and Psychiatry
Journal of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2021, jnnp-2021-326904. ⟨10.1136/jnnp-2021-326904⟩
Journal of Neurology, Neurosurgery, and Psychiatry
Journal of Neurology, Neurosurgery and Psychiatry, 2021, jnnp-2021-326904. ⟨10.1136/jnnp-2021-326904⟩

BackgroundSARS-CoV-2 seroconversion rate after COVID-19 may be influenced by disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMO-SD).ObjectiveTo investigate the seroprevalence an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecdf5b2bf3e4203883ac8f3dc17b13ab
https://hal.sorbonne-universite.fr/hal-03471111